Gallagher Kathleen P. 4

What Happened

• Kathleen P. Gallagher, Chief Executive Officer and President of Atrium Therapeutics (RNA), received two compensation awards on April 20, 2026: 102,500 restricted stock units (RSUs) and a derivative award covering 205,000 shares (an option), both reported at $0.00 on the Form 4. No cash was paid — these are equity compensation grants, not open-market purchases or sales.

Key Details

• Transaction date: 2026-04-20; Form 4 filed: 2026-04-22 (filed timely).
• Reported acquisition price: $0.00 for both awards; total cash reported = $0.
• Shares owned after transaction: not disclosed in the filing excerpt provided.
• Footnote F1 (RSUs): 25% vest on March 20, 2027; remaining RSUs vest in three substantially equal yearly installments thereafter, subject to continued service.
• Footnote F2 (option/derivative): 25% of optioned shares vest on March 20, 2027; remaining shares vest in 36 substantially equal monthly installments thereafter, subject to continued service.
• These awards are compensation grants (Transaction code A); no 10b5-1 plan, tax-withholding or late-filing flags noted in the provided data.

Context

• RSUs convert into one share each upon vesting; the option grant becomes exercisable according to its vesting schedule — both are common long-term incentive pay for executives and do not represent immediate stock sales or open-market purchases.
• Because vesting is tied to continued service, the economic benefit to the insider depends on future employment and vesting events. The Form 4 reports the grant but does not imply an immediate change in market holdings or a market transaction.